Method of enhancing lysosomal α-galactosidase A

Details Method of enhancing lysosomal α-galactosidase A Method of enhancing lysosomal α-galactosidase A

2004-06-14

2009-11-24

Jiang, Shaojia Anna (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S317000, C514S277000, C514S281000, C546S219000, C435S208000

Reexamination Certificate

active

07622485

ABSTRACT:
A method of enhancing the activity of lysosomal α-Galactosidase A (α-Gal A) in mammalian cells and for treatment of Fabry disease by administration of 1-deoxy-galactonojirimycin and related compounds.

REFERENCES:
patent: 4639436 (1987-01-01), Junge et al.
patent: 5030628 (1991-07-01), Joyeau et al.
patent: 5030638 (1991-07-01), Partis et al.
patent: 5043273 (1991-08-01), Scudder et al.
patent: 5051407 (1991-09-01), Boshegan et al.
patent: 5192772 (1993-03-01), Yoshikuni et al.
patent: 5250545 (1993-10-01), Tsuroka et al.
patent: 5292750 (1994-03-01), Yoshikuni et al.
patent: 5399567 (1995-03-01), Platt et al.
patent: 5504078 (1996-04-01), Ducep et al.
patent: 5561221 (1996-10-01), Yoshida et al.
patent: 5580884 (1996-12-01), Platt et al.
patent: 5596005 (1997-01-01), Womg et al.
patent: 5622972 (1997-04-01), Bryant et al.
patent: 5643888 (1997-07-01), Rohrschneider
patent: 5656641 (1997-08-01), Platt et al.
patent: 5691306 (1997-11-01), Bergeron et al.
patent: 5786368 (1998-07-01), Platt et al.
patent: 5798366 (1998-08-01), Platt et al.
patent: 5801185 (1998-09-01), Platt et al.
patent: 5844102 (1998-12-01), Sierks et al.
patent: 5863903 (1999-01-01), Lundgren et al.
patent: 5981494 (1999-11-01), Rademacher et al.
patent: 6177447 (2001-01-01), Aerts et al.
patent: 6225325 (2001-05-01), Jacob
patent: 6274597 (2001-08-01), Fan et al.
patent: 6291657 (2001-09-01), Platt et al.
patent: 6465488 (2002-10-01), Butters et al.
patent: 6583158 (2003-06-01), Fan et al.
patent: 6589964 (2003-07-01), Fan et al.
patent: 6599919 (2003-07-01), Fan et al.
patent: 6774135 (2004-08-01), Fan et al.
patent: 6916829 (2005-07-01), Fan et al.
patent: 7141582 (2006-11-01), Fan et al.
patent: 2001/0018090 (2001-08-01), Noda et al.
patent: 2001/0044453 (2001-11-01), Jacob et al.
patent: 2002/0006909 (2002-01-01), Perlmutter et al.
patent: 2002/0095135 (2002-07-01), Meeker et al.
patent: 2002/0115667 (2002-08-01), Walkley et al.
patent: 2278507 (1998-07-01), None
patent: 61-280472 (1986-12-01), None
patent: WO87/03903 (1987-07-01), None
patent: WO 87/03903 (1987-07-01), None
patent: WO 92/00277 (1992-01-01), None
patent: WO92/00277 (1992-01-01), None
patent: WO94/26714 (1994-11-01), None
patent: WO 94/26714 (1994-11-01), None
patent: WO95/19172 (1995-07-01), None
patent: WO99/24401 (1999-05-01), None
patent: WO 99/40435 (1999-08-01), None
patent: WO99/40435 (1999-08-01), None
patent: WO99/062517 (1999-12-01), None
patent: WO00/29556 (2000-05-01), None
patent: WO00/32175 (2000-06-01), None
patent: WO 00/32175 (2000-06-01), None
patent: WO 00/33843 (2000-06-01), None
patent: WO0033843 (2000-06-01), None
patent: WO00/56334 (2000-09-01), None
patent: WO00/62799 (2000-10-01), None
patent: WO01/02862 (2001-01-01), None
patent: WO 01/02862 (2001-01-01), None
patent: WO01/07078 (2001-02-01), None
patent: WO01/10429 (2001-02-01), None
patent: WO 01/21652 (2001-03-01), None
patent: WO02/28348 (2002-04-01), None
patent: WO 02/28348 (2002-04-01), None
Ishii et al. (Archives of Biochemistry and Biophysics, (May 15, 2000) vol. 377, No. 2, pp. 228-233).
Fan et al. (Nature Medicine, (Jan. 1999) vol. 5, No. 1, pp. 112-115).
Ruvinov et al., Monovalent Cations Partially Repair a Conformational Defect in a Mutant Tryptophan Synthase, α2β2 Complex (β-E109A); J. Biol. Chem. 1995; 270: 17333-38.
Zhou et al. A Correction of defective protein trafficking of a mutant HERG potassium channel in human Long QT syndrome, J. Biol. Chem.; 274(44):31123-31126; Oct. 29, 1999.
Jian-Qiang Fan, et al., “Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor,” Nature Medicine 1999; vol. 5, No. 1, pp. 112-115 laccepted.
Naoki Asano, et al. “In Vitro inhibition and intracellular enhancement of lysosmal α-galactosidase A by deoxygalactonojirimycin and its derivatives,” Eur. J. Biochem; vol. 267, pp. 4179-4186 (Accepted ) May 9, 2000.
Barbara A. Foster, et al., “Pharmacological Rescue of mutant p53 conformation and function,” Science; vol. 286, pp. 2507-2510; Dec. 24, 1999.
Hideki Sakahira , et al., “Specific chaperone-like activity of inhibitor of caspase-activated DNase for caspase-activiated DNase,” J. Biol. Chem; vol. 275, No. 11, pp. 8091-8096; Mar. 17, 2000.
Jean-Pierre Morello, et al., “Pharmacological chaperones rescue cell-surface expression and functions of misfolded V2 vasopressin receptor mutants,” J. Clin. Invest; vol. 105, pp. 887-895; Apr. 2000.
Jon A. Burows et al., “Chemical chaperones mediate increased secretion to mutant α1-antitrypsin (α1-AT)Z: A potential pharmacological strategy for prevention of liver injury and emphysema in α1-AT deficiency,” Proc. Natl. Acad. Sci. U.S.A.; vol. 97, No. 4 pp. 1796-1801; Feb. 15, 2000.
Sue Wicker, et al., “Posttranslational quality control: folding, refolding, and degrading proteins,” Science 1999, vol. 286, pp. 1888-1893; Dec. 3, 1999.
Jean-Pierre Morello, et al., “Pharmacological chaperones: A new twist on receptor folding.” TiPS, 2000; vol. 21, pp. 466-469; Dec. 2000.
Ulla E. Petaja-Repo et al., “Ligands act as pharmacological chaperones and increase the efficiency of δopioid receptor maturation,” The EMBO J.; 21(7); 1628-37; (accepted) Feb. 7, 2002.
T. Ohshima et al., “Alpha-Galactosidase A deficient mice: a model of Fabry disease,” Proceedings of the National Academy of Sciences of USA, National Academy of Science, vol. 94, pp. 2540-2544; Mar. 19, 1997.
Naoki Asano et al., “Homonojirirmycin Isomers and N-Alkylated Homonohirirmycins: structural and conformational basis of inhibition of Glycosidases, ” Journal of Medical Chemistry, vol. 41, No. 14, Jun. 16, 1998.
Asano et al., “Nitrogen-containing furanose and pyranose analogues fromHyacinthus orientalis.” J. Nat. Prod., 61:625-28; Apr. 24, 1998.
Tip W. Loo, et al., “Correction of defective protein kinesis of human P-glycoprotein mutants by substrates and modulators,” J. Biol. Chem. 1997; vol. 272, No. 2, pp. 709-712.
C. Randall Brown, et al., “Chemical chaperones correct the mutant phenotype of the F508 cystic fibrosis transmembrane conductance regulator protein.” Cell Stress & Chaperones 1996; vol. 1 No. 2, pp. 1117-1125.
Ronald C. Rubenstein, et al., “In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylgutyrate in cystic fibrosis epithelial cells containing F508-CFTR,” Pharmacologic Correction of F508-CFTR 1997; vol. 100, No. 10, pp. 2457-2464.
Galina Kuznefsov, et al., “Folding of secretory and membrane proteins,” New Engl. J. Med. 1998; vol. 339, No. 23, pp. 1688-1695.
F. M. Platt et al., “Prevention of lysosomal storage in Tay Sachs mice treated with N-butyldeoxynojirimycin,” Science 1997; vol. 276, pp. 428-431.
T. Okumiya et al., “Galactose stabilizes various missence mutants of alpha-galactosidase in Fabry disease,” Biochem, Biophys Res. Comm. 1997; vol. 214, pp. 1219-1224.
Naoki Ansano et al., “Homojirimycin iomers and glycosides fromAglaonema treubil,” J. Nat. Prod. 1997; vol. 60, p. 98.
A. M. Hurtley and A. Helenius, “Protein oligomerization in the endoplasmic reticulum,” Annu. Rev. Cell Biol 1989; vol. 5, pp. 277-307.
M. P. Dale et al., “Reversible inhibitors of beta-glucosidase,” Biochemistry 1985; vol. 24, pp. 3530-3539.
Frances M. Platt, et al., “N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis,” J. Biol. Chem. 1994, vol. 269, No. 11, pp. 8362-8365.
Frances M. Platt et al., “N-butyldeoxyglactonorjirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing,” J. Biol. Chem. 1994; vol. 269, No. 43, pp. 27108-27114.
Pobojewski et al., “Experimental drug reverses effects of Fabry disease,” The University Records (Univ. of Michigan), vol. 55, No. 34, p. 11, Jun. 2000.
Asano

Affiliated with

Also associated with

Rating

Method of enhancing lysosomal α-galactosidase A does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of enhancing lysosomal α-galactosidase A, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of enhancing lysosomal α-galactosidase A will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4122620